Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + trametinib
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Durvalumab + trametinib is an investigational combination therapy consisting of two agents with distinct mechanisms of action. Durvalumab is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to enhance T-cell mediated immune responses against tumor cells. Trametinib is a small molecule inhibitor of mitogen-activated protein kinase kinase (MEK) 1 and 2, components of the MAPK/ERK pathway involved in cell proliferation and survival. The rationale for combining these drugs is to leverage MEK inhibition to modulate the tumor microenvironment and potentially increase the efficacy of immune checkpoint blockade by enhancing T-cell activation or infiltration. This combination has been studied in phase II clinical trials for metastatic colorectal cancer (MSS mCRC), where it was found to be tolerable but showed limited clinical activity[5].
- Other names
- durvalumab + trametinib
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + trametinib.